Brianna LaPaglia Warns People Using Ozempic Without Medical Need That They Could Be Putting Their Health at Risk
Guest Contributor
Brianna “Chickenfry” LaPaglia is not holding back when it comes to the booming trend of Ozempic and similar medications being used for rapid weight loss. In a recent TikTok video, the 26-year-old influencer delivered a blunt warning to people she believes are using Ozempic without a medical need, sparking a fresh wave of conversation around GLP-1 drugs, body image, and the realities of disordered eating.
In the clip, which she framed as “no tea, no shade, no hate, just some field research,” LaPaglia shared that “every single bitch I know is on Ozempic.” She emphasized that many of these people do not meet the typical profile for needing the medication. To illustrate her point, she compared it to her own situation. She acknowledged that she could probably “lose a couple” pounds but stressed that she does not actually need Ozempic for medical reasons.
YouTube/E! News
Her conclusion was intentionally dramatic and attention grabbing. She addressed those using the drug unnecessarily with the line, “You’re gonna die. You’re all gonna die.” The stark statement captured exactly how alarmed she feels about what she sees as casual or cosmetic use of a serious prescription drug, and it quickly circulated across social media.
Ozempic is a GLP-1 receptor agonist given as a once-weekly injection to help treat type 2 diabetes. It is designed to improve blood sugar control and is commonly prescribed for people whose diabetes has not been adequately managed with other methods. In recent years, it has also become widely known as a weight-loss medication, even though that use is often off-label. Other drugs in this category include Mounjaro, Zepbound, and Wegovy, all of which have been part of a broader cultural conversation about fast weight loss, changing body standards, and health.
Health organizations have raised concerns about the risks of using GLP-1 medications when they are not medically indicated. According to information cited from Baptist Health, possible dangers include gallbladder issues, kidney problems, and the potential for nutrient deficiencies. These are not minor side effects and can have serious long-term consequences. Against that backdrop, LaPaglia’s exaggerated “you’re all gonna die” comment underlines how seriously she believes people should take the decision to use these drugs and the need for qualified medical guidance.
What makes her comments particularly striking is the context of her own recent mental and physical health journey. Only weeks before addressing Ozempic, LaPaglia opened up about her struggles with disordered eating and anxiety in a candid conversation on the “Real Pod” podcast. Her story adds another layer to the dialogue about weight loss medications, because it shows how complex and fragile someone’s relationship with food and body image can be.
YouTube/E! News
On the podcast, LaPaglia described experiencing what she called an “anxiety-induced eating disorder.” She explained that she felt constantly nauseous, and that eating almost always led to vomiting. To cope, she began avoiding food as much as possible because she associated meals with getting sick or feeling intense anxiety. Over time, this pattern took a serious toll on her health and her weight.
She shared that she hit “rock bottom” in the fall of 2023. That period marked her “lowest weight,” a point at which her physical condition alarmed those closest to her. When she visited home, family members reacted with shock. She remembered them saying “Oh, my gosh” when they saw how thin she had become. Her body was showing clear signs of distress. She described being anemic, covered in bruises, and deeply depleted.
According to LaPaglia, living in that state for so long normalized it in her mind. Her body adjusted to the undernourished routine, and coping with constant anxiety became her baseline. Only when her mental health began to stabilize a bit, and when she was able to truly see herself in the mirror, did she recognize just how unhealthy she had become. That realization appears to have been a turning point, one that guided her toward recovery.
She recalled that she had very little energy and wanted to sleep all day, yet still struggled to eat. Rebuilding a healthier connection with food required active, sustained effort. She worked to separate mealtimes from feelings of sickness or anxious anticipation. As she described it, the pattern had effectively created an eating disorder that she did not know how to identify or manage for a long time.
Over time, LaPaglia gained about 25 pounds back, which she described as a return to a healthier weight. That process was not instant. She noted that it took four to five months to reach a more stable place physically and mentally. The change included not just weight restoration, but also a shift in mindset as she worked toward a healthier relationship with eating and her body.
She characterized the journey as “a f***ing process,” emphasizing that there were no quick fixes. Instead, her progress unfolded gradually, and she highlighted the role of consistency over time. Her experience aligns with what many people encounter in recovery from disordered eating, where meaningful change often requires patience, support, and self-awareness rather than an overnight transformation.
In that light, her critique of Ozempic use by people who do not medically need it lands differently. It comes from someone who has seen how fragile health can be when food intake is disrupted, whether by anxiety, restrictive patterns, or outside pressures. While her language about Ozempic is intentionally provocative, it also reflects a broader concern about shortcuts, body image demands, and the risks people may overlook when chasing rapid weight loss.
Her story illustrates a contrast between the promise of rapid change through medication and the reality of slow, often difficult healing. For LaPaglia, getting back to a healthy weight and mindset took months, not weeks, and required confronting the underlying anxiety that affected every meal. Her perspective adds a personal, lived-in dimension to ongoing debates about GLP-1 medications and the cultural fascination with quick results.
For anyone watching this conversation unfold, her comments serve as a reminder that decisions about medications like Ozempic, Mounjaro, Zepbound, and Wegovy should always involve careful medical evaluation. At the same time, her openness about anxiety and disordered eating highlights how important it is to prioritize mental health and long-term well-being, not just the number on a scale.